Active Ingredient History
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adenocarcinoma, Clear Cell (Phase 2)
Adenocarcinoma, Mucinous (Phase 2)
Adenocarcinoma of Lung (Phase 3)
Adrenal Gland Neoplasms (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Anemia (Phase 1)
Anus Neoplasms (Phase 3)
Appendicitis (Phase 2)
Astrocytoma (Phase 2)
Basal Cell Nevus Syndrome (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 1/Phase 2)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Acinar Cell (Phase 2)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Endometrioid (Phase 2)
Carcinoma, Giant Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Merkel Cell (Phase 3)
Carcinoma, Mucoepidermoid (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Carcinosarcoma (Phase 2)
Castration (Phase 2)
Cholangiocarcinoma (Phase 3)
Chondrosarcoma (Phase 2)
Chordoma (Phase 2)
Choriocarcinoma (Phase 2)
Chromatin (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
COVID-19 (Phase 2)
Cystadenocarcinoma, Mucinous (Phase 2)
Cystadenocarcinoma, Serous (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
DNA Mismatch Repair (Phase 1)
Drugs, Investigational (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibrosarcoma (Phase 2)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
GATA2 Deficiency (Phase 1)
Genital Neoplasms, Male (Phase 2)
Germ Cells (Phase 2)
Gestational Trophoblastic Disease (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 2)
Gliosarcoma (Phase 2/Phase 3)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 3)
Healthy Volunteers (Phase 1)
Hemangiosarcoma (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 1)
Hepatitis B (Phase 2)
Hepatitis C (Phase 2)
Hepatoblastoma (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 2)
Immunotherapy (Phase 1/Phase 2)
Infusions, Intravenous (Phase 4)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1/Phase 2)
Kidney Diseases (Phase 2)
Kidney Neoplasms (Phase 4)
Larynx (Phase 1/Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Lip (Phase 1/Phase 2)
Lip Diseases (Early Phase 1)
Liposarcoma (Phase 2)
Liver Neoplasms (Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 1/Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 1/Phase 2)
Lymphomatoid Granulomatosis (Phase 1/Phase 2)
Melanoma ()
Meningeal Carcinomatosis (Phase 2)
Meningioma (Phase 1/Phase 2)
Mesothelioma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms by Site (Phase 2)
Neoplasms, Multiple Primary (Phase 3)
Nerve Sheath Neoplasms (Phase 1)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Neurofibrosarcoma (Phase 2)
Oncogenes (Phase 1)
Oropharyngeal Neoplasms (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 1)
Ovarian Neoplasms (Phase 2)
Paget Disease, Extramammary (Phase 2)
Pancreatic Neoplasms (Phase 2)
Papillomavirus Infections (Phase 2)
Paraganglioma (Phase 2)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 2)
Perivascular Epithelioid Cell Neoplasms (Phase 2)
Pharyngeal Neoplasms (Phase 1/Phase 2)
Pheochromocytoma (Phase 2)
Pituitary Diseases (Phase 2)
Pituitary Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 1)
Prostatic Diseases (Phase 2)
Prostatic Neoplasms (Phase 3)
Proto-Oncogene Proteins c-kit (Phase 1)
Pseudomyxoma Peritonei (Phase 2)
Rectal Neoplasms (Phase 2)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 2)
Sarcoma, Kaposi (Phase 2)
Sarcoma, Synovial (Phase 2)
Seminoma (Phase 2)
Sezary Syndrome (Phase 1/Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 3)
Testicular Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 2)
Tracheal Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
Wilms Tumor (Phase 2)
Xeroderma Pigmentosum (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
